Osteoarthritis – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Osteoarthritis – Pipeline Review, H2 2020’, provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteoarthritis

– The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects

– The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P-Pharma SAS

Abiogen Pharma SpA

Ablynx NV

Aclaris Therapeutics Inc

Adare Pharmaceuticals Inc

Akaal Pharma Pty Ltd

AKL Research and Development Ltd

Algomedix Inc

Amgen Inc

Amplicore Inc

Amzell BV

Arthrogen BV

AskAt Inc

Asta Pharmaceuticals Co Ltd

Atlanthera

Aurealis Pharma AG

Axsome Therapeutics Inc

Bioiberica SAU

Bioorg3.14 LLC

BioStem Technologies Inc

Bone Therapeutics SA

BRIM Biotechnology Inc

CAR-T (Shanghai) Biotechnology Co Ltd

CarthroniX Inc

Cells for Cells SA

CellTex Therapeutics Corp

Cellular Biomedicine Group Inc

Chondrogenix Ltd

Chugai Pharmaceutical Co Ltd

Cocoon Biotech, Inc.

Corestem Inc

Cynata Therapeutics Ltd

Cytonics Corp

Daewoong Pharmaceutical Co Ltd

DNX Biopharmaceuticals Inc

Dongkook Pharmaceutical Co Ltd

Eli Lilly and Co

Ensol Biosciences Inc

Eternity Bioscience Inc

Evgen Pharma Plc

Flexion Therapeutics Inc

Galapagos NV

GeneFrontier Corp

Genequine Biotherapeutics GmbH

General Regeneratives Shanghai Ltd

Gwoxi Stem Cell Applied Technology Co Ltd

Haplnscience Inc

Histogen Inc

HSRx Group

Inception Therapeutics Inc

InKemia IUCT Group SA

International Stem Cell Corp

Kaken Pharmaceutical Co Ltd

Kang Stem Biotech Co Ltd

Kolon TissueGene Inc

Kukje Pharmaceutical Industry Co Ltd

Levolta Pharmaceuticals Inc

LG Chem Ltd

Link Health Group

Lubris Biopharma

Luye Pharma Group Ltd

MDimune Inc

Medicrinia Co Ltd

MediPost Co Ltd

Medivir AB

Meluha Life Sciences Sdn Bhd

Merck KGaA

Meridigen Biotech Co Ltd

Mesoblast Ltd

MetrioPharm AG

Mor Research Applications Ltd

Nanode Therapeutics Inc

NeuroBo Pharmaceuticals Inc

New York R&D Center for Translational Medicine and Therapeutics Inc

Nordic Bioscience AS

Novartis AG

Orbsen Therapeutics Ltd

OrthoTrophix Inc

Paradigm Biopharmaceuticals Ltd

Peptinov SAS

Personalized Stem Cells Inc

Pfizer Inc

Philogen SpA

PhytoHealth Corp

Plakous Therapeutics Inc

Progenitor Therapeutics Ltd

ProteoThera Inc

Regeneus Ltd

Regenosine Inc

Regulaxis SAS

Ribomic Inc

Rottapharm Biotech Srl

Samumed LLC

Sclnow Biotechnology Co Ltd

Seikagaku Corp

Serene LLC

Shionogi & Co Ltd

SL Bigen Inc

Steminent Biotherapeutics Inc

Stempeutics Research Pvt Ltd

Synartro AB

Synerkine Pharma BV

Synokem Pharmaceuticals Ltd

Taiwan Bio Therapeutics Co Ltd

Traverse Biosciences Inc

Unicocell Biomed Co Ltd

Unity Biotechnology Inc

WEX Pharmaceuticals Inc

WNT Scientific LLC

Xalud Therapeutics Inc

Xintela AB

Yooyoung Pharm Co Ltd

Zimmer Biomet Holdings Inc

Table of Contents

Table of Contents

Introduction

Osteoarthritis - Overview

Osteoarthritis - Therapeutics Development

Osteoarthritis - Therapeutics Assessment

Osteoarthritis - Companies Involved in Therapeutics Development

Osteoarthritis - Drug Profiles

Osteoarthritis - Dormant Projects

Osteoarthritis - Discontinued Products

Osteoarthritis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Osteoarthritis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Osteoarthritis – Pipeline by 4P-Pharma SAS, H2 2020

Osteoarthritis – Pipeline by Abiogen Pharma SpA, H2 2020

Osteoarthritis – Pipeline by Ablynx NV, H2 2020

Osteoarthritis – Pipeline by Aclaris Therapeutics Inc, H2 2020

Osteoarthritis – Pipeline by Adare Pharmaceuticals Inc, H2 2020

Osteoarthritis – Dormant Projects, H2 2020

Osteoarthritis – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Osteoarthritis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports